Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination

Meylan, Sylvain; Livio, Françoise; Foerster, Maryline; Genoud, Patrick James; Marguet, François; Wuerzner, Grégoire

doi:10.1161/hypertensionaha.121.17316

Cited by 69 publications

(81 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings extend those by Meylan et al [4] who described 9 patients with stage III hypertension after the Pfizer/BioNTech vaccine. In the present study we had the opportunity to investigate self-measured home BP before and after vaccination.…”

supporting

confidence: 90%

See 1 more Smart Citation

Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine

Zappa

Verdecchia²,

Spanevello

et al. 2021

European Journal of Internal Medicine

View full text Add to dashboard Cite

supporting

confidence: 90%

“…However, some concerns have been raised regarding the safety of SARS-CoV-2 vaccines, largely based on reports of serious thromboembolic events after vaccination [1] . There are also anecdotal data of systemic reactions to vaccination including hypertension [4] and tachycardia [5] .…”

mentioning

confidence: 99%

Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine

Zappa

Verdecchia²,

Spanevello

et al. 2021

European Journal of Internal Medicine

View full text Add to dashboard Cite

“…Meylan et al, in their study, reported a case series of nine patients with stage III hypertension after mRNA-Based COVID-19 vaccination; later, it was found that eight out of nine patients had a history of hypertension and were on medication. 53 As reporting of adverse events considers any events post-administration of a drug or vaccines, causality assessment of all the reported adverse events must be done to conclude. Moreover, time from exposure to adverse events needs to be analyzed to determine whether a particular event is causally associated with the vaccine.…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database

Kaur¹,

Dutta²,

Charan³

et al. 2021

IJGM

View full text Add to dashboard Cite

Background: Thirteen COVID-19 vaccines are granted emergency approval. It is crucial to monitor their adverse events post vaccination. The present study focuses on cardiovascular adverse events post-COVID-19 vaccination and aims to determine adverse events with the administered vaccine. Methodology: The cardiovascular (CVS) adverse events were extracted for three broad headings (SOCs) -cardiac disorders, vascular disorders, and investigations. Descriptive statistics were reported in the form of percentage and frequency, and the disproportionality analysis was conducted. Results: For the cardiovascular system, 4863 adverse events (AEs) were reported from BNT162b2 Pfizer, 1222 AstraZeneca, Moderna, and other COVID-19 vaccines. Common adverse events observed with vaccines under study were tachycardia (16.41%), flushing (12.17%), hypertension (5.82%), hypotension (3.60%) and peripheral coldness (2.41%). Based on disproportionality analysis (IC 025 values), acute myocardial infarction, cardiac arrest, and circulatory collapse were linked to the vaccines in the age group >75 years. Hypertension, severe hypertension, supraventricular tachycardia, sinus tachycardia, and palpitations were associated across all age groups and either gender. Amongst the investigations, abnormal ECG findings raised C-reactive protein, elevated D dimer, and troponin were reported in specific age groups or gender or all subjects. Conclusion: Although cardiovascular events have been reported with the COVID-19 vaccines, the causality is yet to be established because such CVS AEs are also usually associated with the general public even without intervention. Hence, people should be administered these vaccines, and sustained monitoring of these AEs should be done.

show abstract

“…Although the fluctuation of BP is not considered as part of the AEFI, these observations can significantly affect subjects with co-morbidities. This concern seems valid as there is a case series recently published on eight vaccinees who experience elevated high BP after receiving the vaccine 7 . This observation is a valid concern and warrants further investigation on the relationship between vaccine and BP levels.…”

Section: Introductionmentioning

confidence: 96%

BNT162b2 COVID-19 VACCINATION AND ITS EFFECT ON BLOOD PRESSURE

Tan

Salleh

Man

et al. 2021

Preprint

View full text Add to dashboard Cite

This study aims to explore the trends of systolic blood pressure (SBP), diastolic BP (DBP), mean arterial pressure (MAP) and pulse pressure (PP) before and 15-minutes after two doses of the BNT162b2 vaccine, which were administered 21 days apart. This vaccine safety active surveillance study was carried out on 15th-16th March (first dose) and 5th-6th April 2021 (second dose), in academic hospital. . Vaccinees above 18 years old, SBP, DBP, MAP and PP pre- and 15 minutes post-vaccination for both doses were analysed. Study outcomes were mean of BP, mean of BP changes, and BP trends measurements. A total of 287 vaccinees were included. A quarter (n=72) had decreased DBP ≥ 10mmHg (mean DBP deceased: 15mmHg, 95%CI: 14-17mmHg) after the first dose, and 12.5% post-second dose (mean DBP decreased: 13mmHg, 95%CI: 12-15mmHg). Post-first dose, 28.6% (n= 82) were found to have widened PP > 40mmHg. After the first dose, those who had elevated and decreased SBP ≥ 20mmHg were 5.2% and 4.9%, respectively. Eleven percent (n = 32) had decreased SBP ≥ 20mmHg post-second dose, nevertheless the psychology effect cannot be ruled out. The BNT162b2 vaccine was generally well tolerated. BP changes after vaccination emphasizes the need for monitoring.

show abstract

Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination

Cited by 69 publications

References 5 publications

Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine

Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine

Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database

BNT162b2 COVID-19 VACCINATION AND ITS EFFECT ON BLOOD PRESSURE

Contact Info

Product

Resources

About